Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors
- Shilpa Singh
- Catherine E. Gleason
- Min Fang
- Yasmin N. Laimon
- Vishal Khivansara
- Shanhai Xie
- Yavuz T. Durmaz
- Aniruddha Sarkar
- Kenneth Ngo
- Varunika Savla
- Yixiang Li
- Muhannad Abu-Remaileh
- Xinyue Li
- Marie-Anais Locquet
- Bishma Tuladhar
- Ranya Odeh
- Frances Hamkins-Indik
- Daphne He
- Miles W. Membreno
- Meisam Nosrati
- Nathan N. Gushwa
- Siegfried S. F. Leung
- Breena Fraga-Walton
- Luis Hernandez
- Miguel P. Baldomero
- Bryan M. Lent
- David Spellmeyer
- Joshua F. Luna
- Dalena Hoang
- Yuliana Gritsenko
- Manesh Chand
- Megan K. DeMart
- Sammy Metobo
- Chinmay Bhatt
- Justin A. Shapiro
- Kai Yang
- Nathan J. Dupper
- Andrew T. Bockus
- Jinshu Fang
- Ramesh Bambal
- Peadar Cremin
- John G. Doench
- James B. Aggen
- Li-Fen Liu
- Bernard Levin
- Evelyn W. Wang
- Iolanda Vendrell
- Roman Fischer
- Benedikt Kessler
- Prafulla C. Gokhale
2025-08-20